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ORIGINAL ARTICLE INFECTIOUS DISEASESRecurrent Clostridium difﬁcile infection is associated with increased
mortalityM. A. Olsen1,2, Y. Yan2,3, K. A. Reske1, M. D. Zilberberg4,5 and E. R. Dubberke1
1) Division of Infectious Diseases, 2) Division of Public Health Sciences, 3) Department of General Surgery, Washington University School of Medicine, St Louis,
MO, 4) EviMed Research Group, LLC, Goshen and 5) University of Massachusetts, Amherst, MA, USAAbstractClostridium difﬁcile infections (CDI) are associated with decreased survival, and up to 30% of CDI patients may experience a recurrence. Data
on the impact of recurrent CDI on mortality are scarce. The purpose of this study was to determine whether recurrent CDI was
independently associated with decreased 6-month survival compared with patients with CDI who did not develop a recurrence. We
performed a retrospective cohort study at an academic, urban, tertiary care hospital. Data were collected from the electronic medical
record and chart review. CDI patients were followed for 180 days from the end of their index hospital discharge or end of index CDI
antibiotic treatment, whichever was later, to determine mortality. Kaplan–Meier analysis was used to compare patient mortality by
recurrent CDI status. Cox proportional hazards models were used to determine independent risk factors for death within 180 days. In
all, 3958 patients aged  18 years who developed an initial CDI episode from 2003 to 2009, including 421 patients with recurrent CDI,
were included in the study. Thirty-six per cent of persons with recurrent CDI died within 180 days, compared with 26% of persons
without CDI recurrence (log-rank p <0.001). Recurrent CDI was associated with signiﬁcantly higher hazards of death within 180 days,
adjusting for demographics, comorbidities and medications received during the index CDI hospitalization (hazard ratio 1.33; 95% CI
1.12–1.58). Recurrent CDI is associated with signiﬁcantly increased risk of death within 6 months after completion of their initial CDI
treatment compared with CDI patients who do not develop a recurrence.
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E-mail: molsen@dom.wustl.eduIntroductionClostridium difﬁcile infections (CDI) are associated with
decreased survival, but CDI mortality estimates vary widely.
Crude mortality in CDI patients ranges from <5% to >40%
[1–6], and the direct attributable mortality of CDI has been
estimated to be from 4 to 7% [1,2,7]. In a review of CDI studies,Microbiol Infect 2015; 21: 164–170
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.08.017Karas et al. estimated that the attributable mortality associated
with CDI was 5.99%; the pooled attributable mortality
increased to 8.03% when only studies published since 2000
were included [8]. The publications included in this review
included a variety of study designs, patient populations and
mortality surveillance periods (30 days to 1 year post-CDI
infection). All of these differences probably contribute to the
variance in mortality estimates in the published studies.
Up to 30% of patients with CDI experience a recurrence
[9,10], but data on mortality after recurrent CDI are scarce.
Pepin et al. reported that 9.3% of patients who developed
recurrent CDI died within 30 days of recurrence [11], and
Taori et al. reported that 16.4% of patients who developed
recurrent CDI died within a year of recurrence with deathious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Olsen et al. Recurrent CDI and mortality 165attributable to CDI [12]. To the best of our knowledge, these
are the only estimates of mortality in patients with recurrent
CDI, and no studies have been published on mortality associ-
ated with recurrent CDI from healthcare facilities in the USA.
The purpose of this study was to determine whether recurrent
CDI was independently associated with increased 6-month
mortality in a retrospective cohort of hospitalized patients in
the USA.Materials and methodsStudy design
This study was conducted at Barnes-Jewish Hospital (BJH), an
academic tertiary care facility in St Louis, MO, USA. CDI pa-
tients 18 years of age were identiﬁed by querying the hos-
pital’s Medical Informatics database for all patients with positive
C. difﬁcile toxin assay results during an inpatient hospitalization
from 1 January 2003 to 31 December 2009. Two toxin assays
were used during the study period (TechLab C. difﬁcile Toxin A/
B II before July 2004 and after May 2009; Remel ProSpec T
C. difﬁcile A/B Assay from July 2004 to May 2009). The BJH
laboratory accepts only diarrhoeal stools for C. difﬁcile testing.
Additional electronic data collected from the Medical Infor-
matics database included demographics, admission and
discharge dates, admission type (e.g. inpatient, emergency
department), International Classiﬁcation of Diseases, 9th Revi-
sion, Clinical Modiﬁcation (ICD-9-CM) diagnosis and procedure
codes, inpatient medications and laboratory results. ICD-9-CM
discharge diagnosis codes from the index admission and any
admissions within the previous year were used to identify un-
derlying comorbidities, classiﬁed by the Charlson–Deyo algo-
rithm [13,14]. All other variables were included only if they
occurred during the patient’s index CDI hospitalization. Elec-
tronic data were supplemented with medical record review to
determine medications upon admission and discharge from the
hospital and whether the patient was diagnosed with recurrent
CDI as an outpatient or at a separate facility. Death dates were
collected from Medical Informatics and the Social Security
Death Index (register of all deaths reported to the Social Se-
curity Administration). The Washington University Human
Research Protection Ofﬁce approved this study.
CDI case deﬁnitions
Each patient’s ﬁrst inpatient hospitalization (with length of
stay >0.75 days) with a positive C. difﬁcile toxin assay during
the study period was deﬁned as the CDI index hospitalization.
A patient with recurrent CDI was deﬁned as a patient who
had documentation of recurrent CDI within 42 days of the
end of index CDI antibiotic treatment or index discharge,Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiologyeither by repeat positive toxin assay or by clinical diagnosis
documented in the medical record (history of a positive lab-
oratory test as an outpatient or at an outside healthcare fa-
cility and symptoms consistent with CDI). Forty-two days was
used as the risk period to develop recurrent CDI based on
the current surveillance deﬁnition of 8 weeks (i.e. 56 days)
between episodes to be considered recurrent CDI [15]. Since
the recommended CDI treatment duration is 10–14 days
[16], the risk period for recurrent CDI after end of treatment
for the surveillance deﬁnition is 42–46 days. Patients were
followed for 180 days from their index discharge or the end
of index CDI antibiotic treatment (whichever occurred later)
to determine mortality.
Exclusion criteria
Patients with a documented history of CDI in the 60 days
before the study period were excluded to prevent enrolment of
any recurrent CDI patients at baseline. Patients who died
during the index admission or were discharged to a hospice
were excluded.
Statistical analysis
Log-rank tests were used to compare patient mortality by
recurrent CDI status. Cox proportional hazards models were
used to determine univariate and multivariable risk factors for
death within 180 days of index discharge or end of index CDI
antibiotic treatment. Variables with p 0.2 on univariate anal-
ysis or with clinical/biological plausibility were included in initial
multivariable models. Multivariable Cox proportional hazards
models were developed using backward elimination with
p 0.1 to retain variables in the model.
The variable albumin had signiﬁcant missing data; we imputed
missing albumin data under the missing at random assumption
to generate ten imputation data sets. We then identiﬁed risk
factors for death at 180 days using univariate and multivariable
analyses in each of the ten imputation data sets. The risk factors
for death identiﬁed were the same in all ten data sets.
We evaluated the appropriate functional form of all contin-
uous variables with a restricted cubic spline function with
common knots across the ten data sets. The necessity of the
spline in each data set was determined with graphic plots and
the likelihood ratio test of the model with spline terms
compared with the model without the spline terms. Parameter
estimates and their standard errors were pooled over the ten
data sets using Rubin’s rule [17]. Hazard ratios (HR) and 95%
conﬁdence intervals were based on the pooled estimates. The
Kaplan–Meier curves of mortality probability for recurrent
versus non-recurrent CDI were produced using the pooled
(averaged) baseline hazard function across the ten imputation
data sets and Rubin’s rule-pooled Cox proportional hazardsand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 164–170
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CDI.
Statistical analyses were performed with SPSS version 21
(IBM Corporation, Armonk, NY, USA), SAS version 9.3 (SAS
Institute, Cary, NC, USA), and R (R Foundation, Vienna,
Austria), with the R mice package. All statistical testing was
two-tailed with signiﬁcance at the α level 0.05.ResultsThe retrospective cohort included 3958 patients with CDI
during an index hospitalization from 2003 to 2009, 421 (11%) of
whom developed recurrent CDI within 42 days of index hos-
pitalization discharge or the end of index CDI therapy. Sixty-
two (15%) of the recurrent CDI patients were diagnosed and
treated as outpatients; 119 (28%) recurrent CDI cases did not
have a repeat positive toxin at BJH but had documentation in
their medical record of recurrent CDI diagnosed as an outpa-
tient or another healthcare facility. Of these, 86 (72%) had
record of a positive toxin assay (or other laboratory test) with
diagnosis date available. All of the recurrent CDI cases identi-
ﬁed without a positive toxin at BJH had clinical symptoms
compatible with CDI and response to treatment documented in
the medical record.
Factors associated with mortality within 180 days in uni-
variate Cox analysis are given in Table 1, and these included
numerous demographic characteristics, comorbidities, in-
fections, and medications received during the patient’s index
CDI admission. Duration and type of index CDI antibiotic
treatment were not associated with mortality (p >0.05).
Overall mean survival among the population was 149 days. The
mean survival time for recurrent CDI cases was 140 days
versus 150 days for non-recurrent CDI case patients (log-rank
p <0.001). Mortality rates at 30, 60, 90 and 180 days are given in
Table 2. The Kaplan–Meier curves for death within 180 days
for patients with recurrent CDI versus patients without a
recurrence of their CDI are presented in Fig. 1. Overall, 26.8%
(n = 1062) of the patients died within 180 days of their index
CDI discharge date/end of index antibiotic therapy. There was
no signiﬁcant difference in the percentage of recurrent versus
non-recurrent CDI patients alive at 30 days, but mortality was
of borderline signiﬁcance at 60 days and was signiﬁcantly higher
among patients with recurrent CDI at 90 and 180 days
(Table 2). By 180 days, 36% of patients with recurrent CDI had
died, compared with 26% of patients who did not have recur-
rence (p <0.001).
Factors signiﬁcantly associated with mortality within 180
days in multivariable analysis are given in Table 3. Recurrent
CDI was associated with 33% higher hazards of deathClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectcompared with no recurrence within 42 days after completion
of index CDI treatment (95% CI 1.12–1.58), controlling for
demographic characteristics, comorbidities and medications
received during the index hospitalization. The characteristics
most strongly associated with mortality in the multivariable
model were comorbidities, including leukaemia or lymphoma
(HR = 2.36), metastatic solid tumour (HR = 2.47) and HIV/
AIDS (HR = 2.36). Patients whose index CDI hospitalization
was classiﬁed as surgical had signiﬁcantly lower hazards of death
(HR = 0.78; 95% CI 0.68–0.90) than patients whose index
hospitalization was classiﬁed as a medical admission.DiscussionTo our knowledge, this is only the third published study
examining mortality associated with recurrent CDI, and the
ﬁrst from a healthcare facility in the USA. Pepin et al. reported
that 9.3% of patients with at least one CDI recurrence died
within 30 days of recurrence [11]. Their estimate of 9.3% crude
mortality at 30 days after recurrence is comparable to our
ﬁnding of 7.8% mortality in patients with recurrent CDI within
30 days of index discharge or the end of index antibiotic
treatment. In a study from Scotland, Taori et al. reported that
16.4% of the patients with recurrent CDI died within 1 year of
recurrence with CDI listed on the death certiﬁcate as a cause of
death [12]. Taori et al.’s estimate is lower than the 36.3% of
patients with recurrent CDI in our current study who died
within 180 days, but this is not surprising, because we identiﬁed
all-cause mortality rather than death speciﬁcally attributed to
CDI.
In a previous study of outcomes associated with CDI at our
hospital, we observed that CDI had a delayed association with
death. In a matched-pairs analysis, mortality in persons with or
without CDI did not begin to diverge until 60 days after CDI
(or hospital discharge for non-CDI patients) [1]. Mitchell et al.
reported similar results in Australia, with survival rates be-
tween CDI and non-CDI patients diverging at 60 days [18]. The
results of our current study show a similar relationship be-
tween mortality in patients with and without recurrent CDI.
The percentage of patients with and without recurrent CDI
who died was similar at 30 days (7.8% vs 8.7%, respectively) but
diverged thereafter. At 60 days, 17.8% of patients with recur-
rent CDI had died versus 14.3% of patients without recurrence,
and the differences in mortality between the two groups
increased incrementally at 90 days and 180 days. Just as CDI
may contribute to a general decline in patient function over
time compared with patients without CDI, recurrent CDI may
precipitate a decline in patient function over time when
compared with patients who do not develop a recurrence.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 164–170
TABLE 1. Univariate Cox analysis of risk factors for death at 180 days after index discharge or end of Clostridium difﬁcile infections
(CDI) index antibiotic treatment
Variable
Alive at 180 days (n [ 2896)
n (%) or median (range)
Died within 180 days (n [ 1062)
n (%) or median (range) p
Recurrent CDI 268 (9) 153 (14) <0.001
Residence in St Louis metro area 1977 (68) 753 (71) 0.090
Female 1397 (48) 518 (49) 0.701
Non-white race 910 (31) 327 (31) 0.780
Case statusa
HCFO/HCFA 1725 (60) 643 (61) Ref
CA 505 (17) 123 (12) <0.001
CO/HCFA or non-BJH HCFA 666 (23) 296 (28) 0.022
Age 60 (18–102) 67 (18–102) <0.001
Index CDI hospitalization length of stay 11 (1–144) 14 (1–137) <0.001
Index CDI admission from healthcare facility 724 (25) 337 (32) <0.001
Index CDI discharged to healthcare facility 711 (25) 432 (41) <0.001
Index CDI surgical admission 1203 (42) 394 (37) 0.005
ICU admission during index hospitalization 937 (32) 333 (31) 0.291
Median income ($) by zip code (quartiles)
45 582 714 (25) 255 (24) Ref
35 946–45 582 723 (25) 242 (23) 0.554
28 737–35 946 738 (26) 262 (25) 0.943
28 737 721 (25) 303 (29) 0.093
Inpatient hospitalizations in 60 days before index CDI hospitalization
0 1822 (63) 556 (52) Ref
1 759 (26) 339 (32) <0.001
 2 315 (11) 167 (16) <0.001
Duration of index CDI antibiotic treatment 13 (1–91) 13 (1–86) 0.926
Index CDI antibiotic treatment
Metronidzole alone 2229 (77) 804 (76) Ref
Metronidazole and oral vancomycin 574 (20) 234 (22) 0.157
Oral vancomycin alone 93 (3) 24 (2) 0.163
Comorbidities/Infections
Myocardial infarction 226 (8) 108 (10) 0.018
Congestive heart failure 557 (19) 326 (31) <0.001
Peripheral vascular disease 190 (7) 100 (9) 0.002
Cerebrovascular disease 180 (6) 98 (9) <0.001
Chronic renal failure 126 (4) 76 (7) <0.001
Dementia 16 (1) 12 (1) 0.013
Chronic obstructive pulmonary disease 662 (23) 305 (29) <0.001
Rheumatological disease 103 (4) 53 (5) 0.039
Peptic ulcer disease 105 (4) 55 (5) 0.022
Liver disease 141 (5) 84 (8) <0.001
Diabetes 746 (26) 302 (28) 0.099
Paraplegia / hemiplegia 69 (2) 17 (2) 0.217
Cancer 503 (17) 296 (28) <0.001
Leukaemia or lymphoma 472 (16) 216 (20) 0.007
Metastatic solid tumour 256 (9) 213 (20) <0.001
HIV/AIDS 47 (2) 27 (3) 0.068
Skin/soft tissue infection 108 (4) 57 (5) 0.039
Pneumonia 364 (13) 185 (17) <0.001
Urinary tract infection 553 (19) 299 (28) <0.001
Organ abscess 21 (1) 13 (1) 0.147
Surgical site infection 83 (3) 25 (2) 0.342
Device-associated infection 119 (4) 45 (4) 0.936
Bacteraemia / endocarditis 473 (16) 229 (22) <0.001
Bone infection 62 (2) 19 (2) 0.523
Clinical sepsis 216 (8) 103 (10) 0.010
Dialysis 158 (6) 115 (11) <0.001
G-tube placement 144 (5) 99 (9) <0.001
Low creatinine clearance (<70 mL/min) 1138 (39) 599 (56) <0.001
Haemoglobin 10.4 (3.1–19.5) 10.0 (3.7–17.1) <0.001
Albumin 3.1 (1–5.1) 2.8 (1.2–4.7) <0.001
White blood cell count during index CDI hospitalization
Normal 1029 (36) 364 (34) Ref
Low (<3.8 × 103 /μL) 423 (15) 170 (16) 0.308
High (>9.8 × 103 /μL) 1444 (50) 528 (50) 0.451
Medications during index CDI hospitalization
Gastric acid suppressor 2298 (79) 906 (85) <0.001
Antifungal 864 (30) 434 (41) <0.001
Vasopressor 868 (30) 315 (30) 0.926
Antibiotics during index CDI hospitalization
IV vancomycin: 0 days 1486 (51) 435 (41) Ref
IV vancomycin: 1–7 days 890 (31) 390 (37) <0.001
IV vancomycin: >7 days 520 (18) 237 (22) <0.001
Fluoroquinolone: 0 days 1746 (60) 603 (57) Ref
Fluoroquinolone: 1–7 days 877 (30) 321 (30) 0.388
Fluoroquinolone: >7 days 273 (9) 138 (13) <0.001
First-generation cephalosporin: 0 days 2440 (84) 923 (87) Ref
First-generation cephalosporin: 1–7 days 388 (13) 125 (12) 0.184
First-generation cephalosporin: >7 days 68 (2) 14 (1) 0.044
Second-generation cephalosporin: 0 days 2755 (95) 1031 (97) Ref
Second-generation cephalosporin: >0 days 141 (5) 31 (3) 0.007
Third-generation cephalosporin: 0 days 2590 (89) 902 (85) Ref
Third-generation cephalosporin: 1–7 days 269 (9) 132 (12) 0.002
Third-generation cephalosporin: >7 days 37 (1) 28 (3) <0.001
Fourth-generation cephalosporin: 0 days 1791 (62) 548 (52) Ref
Continued
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TABLE 1. Continued
Variable
Alive at 180 days (n [ 2896)
n (%) or median (range)
Died within 180 days (n [ 1062)
n (%) or median (range) p
Fourth-generation cephalosporin: 1–7 days 623 (22) 301 (28) <0.001
Fourth-generation cephalosporin: >7 days 482 (17) 213 (20) <0.001
Linezolid: 0 days 2739 (95) 972 (92) Ref
Linezolid: 1–7 days 97 (3) 44 (4) 0.084
Linezolid: >7 days 60 (2) 46 (4) <0.001
β-lactamase inhibitor: 0 days 2468 (85) 864 (81) Ref
β-lactamase inhibitor: 1–7 days 321 (11) 134 (13) 0.126
β-lactamase inhibitor: >7 days 107 (4) 64 (6) 0.001
Aminoglycoside: 0 days 2652 (92) 950 (90) Ref
Aminoglycoside: 1–7 days 196 (7) 93 (9) 0.040
Aminoglycoside: >7 days 48 (2) 19 (2) 0.853
Carbapenem: 0 days 2519 (87) 903 (85) Ref
Carbapenem: 1–7 days 189 (7) 68 (6) 0.937
Carbapenem: >7 days 188 (7) 91 (9) 0.034
Macrolide: 0 days 2611 (90) 936 (88) Ref
Macrolide: 1–7 days 219 (8) 94 (9) 0.190
Macrolide: >7 days 66 (2) 32 (3) 0.141
aHCFO/HCFA, Healthcare facility onset/healthcare facility associated; CA, Community associated; CO/HCFA, Community onset/healthcare facility associated; non-BJH HCFA, non-
Barnes-Jewish Hospital healthcare facility associated.
168 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMIFunctional decline after hospitalization has been demonstrated
to be related to mortality [19,20], and delayed mortality after
other diarrhoeal illnesses has been reported [21–23]; however,
the exact reasons for the delayed effect of CDI and recurrent
CDI on mortality are unknown and warrant further
investigation.
The results of themultivariable analysis indicate that recurrent
CDI is associated with signiﬁcantly decreased survival indepen-
dent of patient demographics, comorbidities and medications
received during their index CDI hospitalization. Patients with
recurrent CDI had 33% higher hazards of death at 180 days
compared with patients without recurrent CDI (p=0.001). Two
variables, surgical admission and receipt of a second-generation
cephalosporin, were associated with decreased likelihood of
death within 180 days. Patients with non-emergent surgical ad-
missions are generally healthier than the overall hospital popu-
lation, and second generation cephalosporins are used almost
exclusively as surgical prophylaxis for gynaecological and intes-
tinal procedures at our institution. Hence, these two variables
probably capture a population of comparatively healthier CDI
patients who are less likely to develop CDI recurrence. Older
age, serious comorbidities (e.g. leukaemia or lymphoma), overall
poor health (e.g. low albumin), and longer courses of antibiotics
(>7 days) during the index CDI hospitalization were associated
with increased likelihood of death within 180 days. Pepin found
renal failure, measured by peak creatinine level, to be anTABLE 2. Mortality at 30, 60, 90 and 180 days in patients with





Died n (%) Log-rank p
30 days 33 (7.8) 306 (8.7) 0.532
60 days 75 (17.8) 506 (14.3) 0.076
90 days 102 (24.2) 627 (17.7) 0.002
180 days 153 (36.3) 909 (25.7) <0.001
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectindependent risk factor for complicated CDI, which included
death within 30 days [11]. Haemodialysis and low estimated
creatinine clearance were signiﬁcantly associated with 180-day
mortality in our study, conﬁrming that renal failure is an impor-
tant risk factor for death after CDI.
The primary limitation of this study is the use of the hospital
microbiology database to identify recurrent CDI cases. To
minimize this bias all patient medical charts were reviewed to
identify additional recurrent CDI cases diagnosed in the
outpatient setting or at other facilities and transferred to BJH
for treatment. These cases were classiﬁed as having recurrent
CDI. However, patients diagnosed and treated for recurrent
CDI entirely as outpatients (with toxin testing sent to an
outside laboratory) or other facilities would not have been
identiﬁed as having a recurrence, potentially biasing our results
toward moderate-to-severe cases of recurrent CDI.FIG. 1. Kaplan–Meier curve of survival at 180 days by recurrent CDI
status.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 164–170
TABLE 3. Factors associated with mortality within 180 days in
Cox proportional hazards model
Variable HR (95% CI) p
Recurrent CDI 1.33 (1.12–1.58) 0.001
Agea 1.48 (1.32–1.67) <0.001
Index CDI admission from a healthcare facilityb 1.17 (1.01–1.34) 0.032
Index CDI discharged to a healthcare facilityb 1.53 (1.32–1.77) <0.001
Index CDI surgical admission 0.78 (0.68–0.90) <0.001
Comorbidities
Metastatic solid tumour 2.47 (2.01–3.03) <0.001
Leukaemia or lymphoma 2.36 (1.97–2.83) <0.001
HIV/AIDS 2.36 (1.58–3.52) <0.001
Liver disease 1.92 (1.53–2.42) <0.001
Congestive heart failure 1.48 (1.29–1.71) <0.001
Rheumatological disease 1.39 (1.05–1.84) 0.021
Cancer 1.33 (1.10–1.60) 0.003
Peptic ulcer disease 1.31 (0.99–1.72) 0.055
Urinary tract infection 1.24 (1.07–1.43) 0.004
Dialysis 1.53 (1.24–1.88) <0.001
G-tube placement 1.33 (1.07–1.66) 0.011
Low estimated creatinine clearance (<70 mL/min) 1.34 (1.16–1.55) <0.001
Haemoglobin (mg/dL) 0.96 (0.92–1.00) 0.031
Albuminc 0.63 (0.53–0.75) <0.001
Medications during index CDI hospitalization
Antifungal 1.25 (1.09–1.44) 0.002
Fluoroquinolone: 0 days Reference
Fluoroquinolone: 1–7 days 0.94 (0.82–1.08) 0.392
Fluoroquinolone: >7 days 1.21 (0.99–1.47) 0.057
Second-generation cephalosporin: 0 days Reference
Second-generation cephalosporin: >0 days 0.54 (0.37–0.78) 0.001
Third-generation cephalosporin: 0 days Reference
Third-generation cephalosporin: 1–7 days 1.10 (0.91–1.33) 0.317
Third-generation cephalosporin: >7 days 1.59 (1.09–2.34) 0.016
β-lactamase inhibitor: 0 days Reference
β-lactamase inhibitor: 1–7 days 1.04 (0.86–1.25) 0.712
β-lactamase inhibitor: >7 days 1.41 (1.08–1.84) 0.011
aResults presented as 75th percentile vs. 25th percentile.
bLong-term care facility, outside hospital, other healthcare facility
cModelled as spline variable. Results presented as 75th percentile versus 25th
percentile.
CMI Olsen et al. Recurrent CDI and mortality 169Another limitation was the lack of data on C. difﬁcile strain.
This is important because the 027/BI/NAP1 strain has been
associated with both increased risk of CDI recurrence and
mortality [24,25]. Data used in this study were subject to the
inherent limitations of retrospective data. Despite adjustment
for a variety of demographics, comorbidities and medications,
residual confounding may exist.
This study has several strengths. The sample size of our CDI
population was large, and a wide variety of demographics,
comorbidities, medications and laboratory and microbiological
data were included in multivariable models. Death dates used to
calculate mortality were collected from multiple sources
(hospital data and the Social Security Death Index), and so any
ascertainment bias with death should be minimal.
Very few data exist on the outcomes of patients with
recurrent CDI. The results of this study suggest that recurrent
CDI is associated with signiﬁcantly increased mortality, with
more than a third of recurrent CDI patients dying within 6
months after completion of index CDI treatment. This mor-
tality estimate may decrease with better ascertainment of CDI
recurrence, particularly recurrent CDI patients with milder
symptoms diagnosed and treated solely as outpatients. In the
time since follow up for this study has ended, many studies have
been published recently describing promising new treatmentClinical Microbiology and Infection © 2014 European Society of Clinical Microbiologystrategies for CDI patients [26–29]. Recurrent CDI was not
the patient characteristic most strongly associated with
increased mortality in multivariable analysis in our study; severe
comorbidities (such as leukaemia/lymphoma, metastatic solid
tumour or HIV/AIDS) were associated with higher hazards of
death. These characteristics are not easily modiﬁable, and
newer treatments for recurrent CDI may not signiﬁcantly
improve survival in these patients. Nevertheless, our results
indicate that recurrent CDI is independently associated with
excess mortality, after adjustment for comorbidities. These
results should be conﬁrmed at other institutions. Our ﬁnding of
increased mortality associated with recurrent CDI should give
further impetus to research on the effect of recurrent CDI on
survival in patients whose recurrent infections were treated
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